Selected in Neurology by CAROFF Jildaz
Authors: Mohr JP, Overbey JR, von Kummer R, Stefani MA, Libman R, Stapf C, Parides MK, Pile-Spellman J, Moquete E, Moy CS, Vicaut E, Moskowitz AJ, Harkness K, Cordonnier C, Biondi A, Houdart E, Berkefeld J, Klijn KJM, Barreau X, Kim H, Hartmann A
Reference: Neurology. 2017 Sep 6;:10.1212/WNL.0000000000004532–9
Published: September 2017
Yesterday, the journal Neurology published a more detailed analysis of the controversial ARUBA trial. Clinical functional impairment of the primary endpoint events (i.e. stroke severity) as well as the association with Spetzler-Martin grade were not analyzed in detail in the earlier publication.
Three important points here:
1) Patients in the medical management arm were less likely to experience primary outcomes (i.e. death or stroke) with functional impairment (as defined as an mRS score >2) than those who underwent intervention after a median follow-up of 33 months
2) The above was found to be the case regardless of Spetzler-Martin grades
3) These results applied for both randomized and treated patients
Periprocedural outcomes and early safety with the use of the Pipeline Flex Embolization Device with Shield Technology for unruptured intracranial an...